Analystreport

BioMarin Pharmaceutical (BMRN) is now covered by Morgan Stanley. They set an "overweight" rating and a $120.00 price target on the stock.

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com